Saturday 17 October 2026
Export PCVX’s income statement to Excel — free account
Vaxcyte, Inc.
PCVX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 61.5% and free cash flow fell 92.6%, each against the same quarter a year earlier.
63.62
1.65
−2.53%
Follow PCVX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(20.83%) | (25.59%) | (30.55%) | (36.51%) | |
| (19.53%) | (23.54%) | (28.14%) | (33.03%) | ||
ROIC |
(42.93%) | (51.34%) | (54.05%) | (57.30%) | |
Return on Tangible Assets |
(36.10%) | (45.66%) | (51.66%) | (69.03%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(4.09) | (4.92) | (5.59) | (6.19) | |
Free Cash Flow |
(557.23) | (669.29) | (780.32) | (894.14) | |
Capital Expenditures |
(15.08) | (13.71) | (10.40) | (12.90) | |
| Other line items | |||||
Cash ROIC |
(12.10%) | (15.76%) | (16.49%) | (21.06%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.82 | 0.86 | 0.81 | 0.83 | |
Depreciation/Fixed assets |
(0.01) | 0.04 | 0.05 | 0.07 | |
Capex/Depreciation |
4.31 | (1.32) | (0.79) | (0.74) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.98) | (4.82) | (5.52) | (6.10) | |
Capex per Share |
(0.11) | (0.10) | (0.07) | (0.09) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates